

Eoin P Brennan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9531013/publications.pdf>

Version: 2024-02-01

46
papers

7,278
citations

257101

24
h-index

233125

45
g-index

53
all docs

53
docs citations

53
times ranked

14872
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide meta-analysis and omics integration identifies novel genes associated with diabetic kidney disease. <i>Diabetologia</i> , 2022, 65, 1495-1509.	2.9	16
2	Decoding microRNA drivers in atherosclerosis. <i>Bioscience Reports</i> , 2022, 42, .	1.1	11
3	Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113167.	2.6	34
4	Therapeutic potential of the FPR2/ALX agonist AT-01-KG in the resolution of articular inflammation. <i>Pharmacological Research</i> , 2021, 165, 105445.	3.1	19
5	Extracellular vesicles from monocyte/platelet aggregates modulate human atherosclerotic plaque reactivity. <i>Journal of Extracellular Vesicles</i> , 2021, 10, 12084.	5.5	32
6	Assessment of differentially methylated loci in individuals with end-stage kidney disease attributed to diabetic kidney disease: an exploratory study. <i>Clinical Epigenetics</i> , 2021, 13, 99.	1.8	29
7	Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A ₄ Mimetics (QNX-sLXms). <i>Journal of Medicinal Chemistry</i> , 2021, 64, 9193-9216.	2.9	18
8	Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function. <i>Nature Reviews Nephrology</i> , 2021, 17, 725-739.	4.1	85
9	Therapeutic potential of pro-resolving mediators in diabetic kidney disease. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113965.	6.6	23
10	Medications Activating Tubular Fatty Acid Oxidation Enhance the Protective Effects of Roux-en-Y Gastric Bypass Surgery in a Rat Model of Early Diabetic Kidney Disease. <i>Frontiers in Endocrinology</i> , 2021, 12, 757228.	1.5	4
11	Promoting resolution in kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 119-127.	1.0	2
12	The Atlas of Inflammation Resolution (AIR). <i>Molecular Aspects of Medicine</i> , 2020, 74, 100894.	2.7	110
13	The Molecular Effects of a High Fat Diet on Endometrial Tumour Biology. <i>Life</i> , 2020, 10, 188.	1.1	4
14	Characterization of the renal cortical transcriptome following Roux-en-Y gastric bypass surgery in experimental diabetic kidney disease. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001113.	1.2	10
15	Dysregulation of the interleukin-17A pathway in endometrial tissue from women with unexplained infertility affects pregnancy outcome following assisted reproductive treatment. <i>Human Reproduction</i> , 2020, 35, 1875-1888.	0.4	11
16	Therapeutic Potential of Lipoxin A ₄ in Chronic Inflammation: Focus on Cardiometabolic Disease. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 43-55.	2.5	40
17	microRNA-155 Is Decreased During Atherosclerosis Regression and Is Increased in Urinary Extracellular Vesicles During Atherosclerosis Progression. <i>Frontiers in Immunology</i> , 2020, 11, 576516.	2.2	26
18	Diagnostic utility of genetic testing in patients undergoing renal biopsy. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005462.	0.5	7

#	ARTICLE	IF	CITATIONS
19	Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 447-458.	1.3	27
20	Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2000-2016.	3.0	135
21	Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A4 mimetics (sLXms). <i>European Journal of Medicinal Chemistry</i> , 2019, 162, 80-108.	2.6	38
22	Specialized pro-resolving mediators in diabetes: novel therapeutic strategies. <i>Clinical Science</i> , 2019, 133, 2121-2141.	1.8	12
23	Lipoxins Regulate the Early Growth Response-1 Network and Reverse Diabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1437-1448.	3.0	48
24	RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor- β and Increasing Resistance to Apoptosis. <i>Diabetes</i> , 2018, 67, 960-973.	0.3	23
25	Specialized Pro-resolving Lipid Mediators: Modulation of Diabetes-Associated Cardio-, Reno-, and Retino-Vascular Complications. <i>Frontiers in Pharmacology</i> , 2018, 9, 1488.	1.6	28
26	Lipoxins Protect Against Inflammation in Diabetes-Associated Atherosclerosis. <i>Diabetes</i> , 2018, 67, 2657-2667.	0.3	60
27	Profibrotic IHG-1 complexes with renal disease associated HSPA5 and TRAP1 in mitochondria. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 896-906.	1.8	13
28	Protective Effect of let-7 miRNA Family in Regulating Inflammation in Diabetes-Associated Atherosclerosis. <i>Diabetes</i> , 2017, 66, 2266-2277.	0.3	130
29	Specialized pro-resolving mediators in renal fibrosis. <i>Molecular Aspects of Medicine</i> , 2017, 58, 102-113.	2.7	22
30	NR4A Receptors Differentially Regulate NF- κ B Signaling in Myeloid Cells. <i>Frontiers in Immunology</i> , 2017, 8, 7.	2.2	33
31	miRNAs in the Pathophysiology of Diabetes and Their Value as Biomarkers. , 2016, , 643-661.		4
32	Mesenchymal Stem Cells Deliver Exogenous MicroRNA-let7c via Exosomes to Attenuate Renal Fibrosis. <i>Molecular Therapy</i> , 2016, 24, 1290-1301.	3.7	286
33	Paricalcitol protects against TGF- β 1-induced fibrotic responses in hypoxia and stabilises HIF- α in renal epithelia. <i>Experimental Cell Research</i> , 2015, 330, 371-381.	1.2	16
34	New genetic loci link adipose and insulin biology to body fat distribution. <i>Nature</i> , 2015, 518, 187-196.	13.7	1,328
35	Genetic studies of body mass index yield new insights for obesity biology. <i>Nature</i> , 2015, 518, 197-206.	13.7	3,823
36	Study of microRNA in diabetic nephropathy: Isolation, quantification and biological function. <i>Nephrology</i> , 2015, 20, 132-139.	0.7	15

#	ARTICLE	IF	CITATIONS
37	Genetic Evidence for a Causal Role of Obesity in Diabetic Kidney Disease. <i>Diabetes</i> , 2015, 64, 4238-4246.	0.3	63
38	Targeting cellular drivers and counter-regulators of hyperglycaemia-associated profibrotic responses in diabetic kidney disease. <i>Experimental Physiology</i> , 2014, 99, 1154-1162.	0.9	9
39	Lipoxins Attenuate Renal Fibrosis by Inducing let-7c and Suppressing TGF β 2R1. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 627-637.	3.0	140
40	Chromosome 2q31.1 Associates with ESRD in Women with Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1537-1543.	3.0	66
41	The Genetics of Diabetic Nephropathy. <i>Genes</i> , 2013, 4, 596-619.	1.0	36
42	New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes. <i>PLoS Genetics</i> , 2012, 8, e1002921.	1.5	216
43	Next-generation sequencing identifies TGF β 1-associated gene expression profiles in renal epithelial cells reiterated in human diabetic nephropathy. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 589-599.	1.8	80
44	Association Testing of Previously Reported Variants in a Large Case-Control Meta-analysis of Diabetic Nephropathy. <i>Diabetes</i> , 2012, 61, 2187-2194.	0.3	77
45	DNA methylation profiling in cell models of diabetic nephropathy. <i>Epigenetics</i> , 2010, 5, 396-401.	1.3	28
46	Comparative analysis of DNA methylation profiles in peripheral blood leukocytes versus lymphoblastoid cell lines. <i>Epigenetics</i> , 2009, 4, 159-164.	1.3	34